Palouse Capital Management's Q3 and Q4 2022: A Look at the Top Holdings Changes
Ava Hoppe | 8 May, 2023
Palouse Capital Management, Inc. is a registered investment advisory firm that manages several portfolios comprised of different investments. One of the things Palouse does is file a 13F form with the Securities and Exchange Commission (SEC) to disclose its holdings at the end of each quarter.
This article will take a closer look at Palouse Capital Management's Q3 and Q4 2022 13F filings, specifically comparing their top holdings changes.
As of Q3 2022, Palouse held 33 unique issuers with an aggregate market value of $1.4 billion. As part of its strategy, Palouse bought and sold securities between Q3 and Q4, resulting in a smaller portfolio of 28 unique issuers and an aggregate market value of $1.3 billion.
Regeneron Pharmaceuticals and BlackRock Inc were the two highest-valued holdings at the end of Q3, with a combined value of $161.5 million. However, Palouse decreased its holdings on both companies, resulting in an approximately 45% decrease in total value.
Broadcom Inc and Thermo Fisher Scientific Inc were two of the biggest increases in holdings between Q3 and Q4. Palouse added over 6,400 shares in Broadcom and over 100 shares in Thermo Fisher. These two holdings combined made up 18% of Palouse's portfolio at the end of Q4, compared to being 8% at the end of Q3.
Another increase in holdings was NXP Semiconductors NV. Palouse added nearly 1,500 shares, resulting in an increase of 19% in total shares held. Lam Research Corporation, SPDR S&P 500 ETF TR, and Home Depot Inc also saw increases in shares held.
Despite holding fewer securities and a lower aggregate market value, Palouse's holdings in Q4 generated a higher percentage increase compared to Q3. In Q3, their holdings decreased by 7% while in Q4, their holdings increased by 9.8%.
In conclusion, Palouse Capital Management's Q3 and Q4 filings show a few significant changes in its holdings. While their two highest-valued holdings at the end of Q3 decreased in value, their increased holdings in Broadcom Inc, Thermo Fisher Scientific Inc, and NXP Semiconductors NV suggest that Palouse is gravitating more towards the technology and semiconductor industries.
Other Posts
- Shore Capital Partners Announces Formation of Empower Aesthetics
- Oxford Asset Management's Q1 2020 vs. Q1 2020 13F Holdings Analysis Reveals Interesting Shifts
- Investment Report: Markston International LLC Q3 2021 vs. Q4 2021
- Analyzing Lincoln Capital Corp's Q4 2022 vs. Q1 2023 13F Holdings Changes
- Steward Partners Investment Advisory, LLC Q3 2022 vs. Q4 2022 13F Holdings Comparison
- Investing Insights: Marathon Partners' Q3 2022 vs. Q4 2022 13F Holdings Comparison
- When Parking Meets Innovation: A Tale of Two Giants, ParkHub and JustPark, Steering Forward Together
- Analyzing RNC Capital Management LLC's Q3 2022 vs. Q4 2022 13F Holdings: Tech Stocks Remain Strong, Energy Companies on the Rise, and Diverse Holdings in Finance, Healthcare, and Consumer Goods
- Analyzing the Third Quarter to Fourth Quarter 2022 Shifts in Holdings for StepStone Group: A Detailed Discussion
- Asset Planning Services, Ltd.: A Comprehensive Look at Q3 2021 vs. Q4 2021 13F Holdings